newsfilter
← Latest News
GlobeNewswire·

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE)